Latest Conference Articles

A look at 13 phase 2 and phase 3 studies with significant implications from EADV 2025's late-breaking sessions.

McCarty explains progress made with new screening options but emphasizes ongoing barriers hindering screening goals and how they need to be addressed.

Skarbinski explains challenges providers face when managing refractory GERD and common misconceptions about its diagnosis and treatment.

Moore describes recent progress in PBC and PSC and how this defined the field of hepatology in 2024, with lasting effects into 2025.

Semaglutide exhibited a 57% reduction in major adverse cardiovascular events compared to tirzepatide in patients with CVD with no prior history of diabetes.

Stewart explains recent advances in eosinophilic gastrointestinal diseases and breaks down new ACG EoE guidelines.

Despite not lowering cardiovascular death or worsening heart failure, composite data did suggest the efficacy of in-hospital initiation of SGLT2 inhibitors.

A lower incidence of all-cause mortality and hospitalization for worsening heart failure proved digitoxin’s noninferiority in this phase 4 trial.

A recap 8 clinical trials in cardiovascular care to know from the European Society of Cardiology Congress 2025.

Despite an excellent safety and tolerability profile and proven efficacy in treating atrial fibrillation, PFA failed to prove superiority to RA.

Alnylam Pharmaceuticals debuts phase 2 KARDIA-3 data at ESC 2025 and advances zilebesiran into a phase 3 outcomes trial.

Olezarsen shows promise in significantly lowering triglyceride levels in patients with hypertriglyceridemia.

The investigative aldosterone synthase inhibitor reduced seated systolic blood pressure in patients with uncontrolled or resistant hypertension compared to placebo.

Aficamten shows significant benefits over metoprolol in treating symptomatic obstructive HCM, potentially changing first-line therapy approaches.

Aficamten displayed superior improvements in peak oxygen uptake and hemodynamics compared to the most commonly used beta-blocker for symptomatically obstructive HCM.

Take a look at 7 major clinical trials to keep an eye on for the upcoming ESC Congress from August 29-September 1, 2025.

This HCPLive Five episode focuses on 5 key ophthalmology updates from the ASRS2025 conference.

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 key dermatology updates from the DERM2025 meeting.

Avacincaptad pegol, pegcetacoplan, and aflibercept 8mg do not increase risk of ocular hypertension and glaucoma, despite having higher volumes.

Results from a recent trial indicated continuously decreasing risks of all forms of retinal vascular occlusion and retinal vein occlusion for 5 years after treatment.

Both trials indicated lasting visual improvements in patients treated with Ixo-vec who had previously received anti-VEGF injections.

These data from the ICONIC-LEAD study were presented at DERM 2025, highlighting the efficacy and safety of icotrokinra in patients with psoriasis.

An interim report from the ongoing trial shows few adverse events resulting from 60 weeks of treatment with the combined AAV vector/dual-transgene cassette.

In this summary of coverage at the DERM 2025 conference, a list of notable stories highlighting acne management strategies is highlighted.

The new, bioerodible intravitreal implant, which periodically releases the tyrose kinase inhibitor vorolanib, may be capable of reducing treatment burden for at least 6 months.

In this list of the top 5 posters featured at the DERM 2025 conference, a variety of recent data are spotlighted in alopecia areata, atopic dermatitis, and other disease states.

The ongoing Archway-Portal extension study indicates the lasting efficacy and safety of ranibizumab dosing via the Port Delivery System.